A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition

Molecular Neurodegeneration

Sam Gandy⁵  Mary Sano⁵  Clara Li¹  Martin A Goldstein³  Amy Aloysi³  Margaret C Sewell¹  Jennifer L Woehr³  Jane Martin⁴  Josef Machac²  Lale Kostakoglu²  Heidi A Bender³  Effie M Mitsis⁵ 

[1] Icahn School of Medicine at Mount Sinai, Alzheimer’s Disease Research Center, One Gustave L. Levy Place, Box 1230, New York, NY 10029, USA;Department of Nuclear Medicine, New York, NY 10029, USA;Department of Neurology, New York, NY 10029, USA;Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10029, USA;James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA

关键词: Neuroimaging;    Alzheimer’s disease;    Clinical series;    PET;    Florbetapir;    Amyvid™;   

Others  :  1215988
DOI  :  10.1186/1750-1326-9-10

 received in 2013-12-31, accepted in 2014-01-30,  发布年份 2014

【 摘 要 】

Background

Identification and quantification of fibrillar amyloid in brain using positron emission tomography (PET) imaging and Amyvid™ ([¹⁸ F] Amyvid, [¹⁸ F] florbetapir, ¹⁸ F-AV-45) was recently approved by the US Food and Drug Administration as a clinical tool to estimate brain amyloid burden in patients being evaluated for cognitive impairment or dementia. Imaging with [¹⁸ F] florbetapir offers in vivo confirmation of the presence of cerebral amyloidosis and may increase the accuracy of the diagnosis and likely cause of cognitive impairment (CI) or dementia. Most importantly, amyloid imaging may improve certainty of etiology in situations where the differential diagnosis cannot be resolved on the basis of standard clinical and laboratory criteria.

Results

A consecutive case series of 30 patients (age 50-89; 16 M/14 F) were clinically evaluated at a cognitive evaluation center of urban dementia center and referred for [¹⁸ F] florbetapir PET imaging as part of a comprehensive dementia workup. Evaluation included neurological examination and neuropsychological assessment by dementia experts. [¹⁸ F] florbetapir PET scans were read by trained nuclear medicine physicians using the qualitative binary approach. Scans were rated as either positive or negative for the presence of cerebral amyloidosis. In addition to a comprehensive dementia evaluation, post [¹⁸ F] florbetapir PET imaging results caused diagnoses to be changed in 10 patients and clarified in 9 patients. Four patients presenting with SCI were negative for amyloidosis. These results show that [¹⁸ F] florbetapir PET imaging added diagnostic clarification and discrimination in over half of the patients evaluated.

Conclusions

Amyloid imaging provided novel and essential data that: (1) caused diagnosis to be revised; and/or (2) prevented the initiation of incorrect or suboptimal treatment; and/or (3) avoided inappropriate referral to an anti-amyloid clinical trial.

【 授权许可】

   
2014 Mitsis et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Solomon PR, Brush M, et al.: Identifying dementia in the primary care practice. Int Psychogeriatr 2000, 12(4):483-493.
• [2]Lopponen M, Raiha I, et al.: Diagnosing cognitive impairment and dementia in primary health care – a more active approach is needed. Age Ageing 2003, 32(6):606-612.
• [3]Wong DF, Rosenberg PB, et al.: In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med 2010, 51(6):913-920.
• [4]Clark CM, Schneider JA, et al.: Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011, 305(3):275-283.
• [5]Lister-James J, Pontecorvo MJ, et al.: Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent. Semin Nucl Med 2011, 41(4):300-304.
• [6]Clark CM, Pontecorvo MJ, et al.: Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort study. Lancet Neurol 2012, 11(8):669-678.
• [7]Jack CR Jr, Wiste HJ, et al.: Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity. Neurology 2013, 81(20):1732-1740.
• [8]Doraiswamy PM, Sperling RA, et al.: Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79(16):1636-1644.
• [9]Fleisher AS, Chen K, et al.: Apolipoprotein E epsilon4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease. Neurobiol of aging 2013, 34(1):1-12.
• [10]Fleisher AS, Chen K, et al.: Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Archives of Neurol 2011, 68(11):1404-1411.
• [11]Johnson KA, Minoshima S: Appropriate use criteria for amyloid PET: a report of the amyloid imaging task force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement 2013, 9(1):1-16.
• [12]Sperling RA, Johnson KA, et al.: Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging 2013, 34(3):822-831.
• [13]Albert MS, DeKosky ST, et al.: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7(3):270-279.
• [14]Johnson KA, Minoshima S, et al.: Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. J Nucl Med 2013, 54(7):1011-1013.
• [15]Johnson KA, Sperling RA: Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement 2013, 9(5 Suppl):572-583.
• [16]Bateman RJ, Xiong C: Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012, 30(9):795-804. 367
• [17]Mintun MA, Larossa GN, et al.: [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006, 67(3):446-452.
• [18]Pike KE, Savage G, et al.: Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007, 130(Pt 11):2837-2844.
• [19]Rosenberg PB, Wong DF, et al.: Cognition and amyloid load in Alzheimer disease imaged with florbetapir F 18(AV-45) positron emission tomography. Am J Geriatr Psychiatry 2013, 21(3):272-278.
• [20]Scholl M, Wall A, et al.: Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers. Neurology 2012, 79(3):229-236.